JP7690285B2 - 結合タンパク質１ - Google Patents

結合タンパク質１ Download PDF

Info

Publication number
JP7690285B2
JP7690285B2 JP2020502992A JP2020502992A JP7690285B2 JP 7690285 B2 JP7690285 B2 JP 7690285B2 JP 2020502992 A JP2020502992 A JP 2020502992A JP 2020502992 A JP2020502992 A JP 2020502992A JP 7690285 B2 JP7690285 B2 JP 7690285B2
Authority
JP
Japan
Prior art keywords
seq
set forth
binding protein
sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527355A5 (https=
JP2020527355A (ja
Inventor
ジェームズ・キャンベル
ヴァレンティーナ・ドゥブリェヴィッチ
ジェームズ・ハンセン
ザーラ・ラトレー
ジアンビン・ジョウ
Original Assignee
ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド
イェール・ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド, イェール・ユニヴァーシティー filed Critical ニュークリアス・セラピューティクス・ピーティーワイ・リミテッド
Publication of JP2020527355A publication Critical patent/JP2020527355A/ja
Publication of JP2020527355A5 publication Critical patent/JP2020527355A5/ja
Priority to JP2023065086A priority Critical patent/JP2023083385A/ja
Application granted granted Critical
Publication of JP7690285B2 publication Critical patent/JP7690285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020502992A 2017-07-17 2018-07-17 結合タンパク質１ Active JP7690285B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065086A JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質１

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762533546P 2017-07-17 2017-07-17
US62/533,546 2017-07-17
US201762596694P 2017-12-08 2017-12-08
US62/596,694 2017-12-08
PCT/US2018/042532 WO2019018426A1 (en) 2017-07-17 2018-07-17 BINDING PROTEINS 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065086A Division JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質１

Publications (3)

Publication Number Publication Date
JP2020527355A JP2020527355A (ja) 2020-09-10
JP2020527355A5 JP2020527355A5 (https=) 2021-08-26
JP7690285B2 true JP7690285B2 (ja) 2025-06-10

Family

ID=65015294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502992A Active JP7690285B2 (ja) 2017-07-17 2018-07-17 結合タンパク質１
JP2023065086A Pending JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質１

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065086A Pending JP2023083385A (ja) 2017-07-17 2023-04-12 結合タンパク質１

Country Status (8)

Country Link
US (5) US20200216568A1 (https=)
EP (1) EP3655432A4 (https=)
JP (2) JP7690285B2 (https=)
CN (1) CN111094338A (https=)
AU (1) AU2018302110B2 (https=)
CA (2) CA3070252A1 (https=)
IL (1) IL272064A (https=)
WO (2) WO2019018426A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6178785B2 (ja) 2011-04-01 2017-08-09 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
CN116529266A (zh) 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
AU2022228255A1 (en) 2021-03-03 2023-09-28 Yale University Compositions and methods for treating skeletal muscle disease
JP2024519169A (ja) * 2021-05-25 2024-05-08 トランスマブ・ピーティーワイ・リミテッド 改善された免疫グロブリンｉ
US20240226311A1 (en) * 2021-05-25 2024-07-11 Transmab Pty Ltd Improved immunoglobulin II
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
EP4448745A4 (en) * 2021-12-15 2025-12-24 Univ Indiana Trustees CELLULAR TARGETING COMPOSITIONS AND METHODS
US20230303719A1 (en) * 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
EP4642488A1 (en) 2022-12-27 2025-11-05 Yale University Antibody drug conjugates
WO2024158824A1 (en) 2023-01-23 2024-08-02 Yale University Antibody oligonucleotide conjugates
EP4683674A1 (en) 2023-03-23 2026-01-28 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN121159711A (zh) * 2024-01-02 2025-12-19 河北神宇生物技术有限公司 一种提高adc药物疗效的重组蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033321A1 (en) 2014-08-28 2016-03-03 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
JP2017503511A (ja) 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615662D0 (en) 2006-08-07 2006-09-13 Affitech As Antibody
CA2907072A1 (en) * 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
WO2015192092A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503511A (ja) 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分
WO2016033321A1 (en) 2014-08-28 2016-03-03 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof

Also Published As

Publication number Publication date
AU2018302110B2 (en) 2024-11-21
US12312417B2 (en) 2025-05-27
AU2018302110A1 (en) 2020-02-06
CA3300582A1 (en) 2026-03-02
IL272064A (en) 2020-03-31
EP3655432A4 (en) 2021-04-14
WO2019018426A1 (en) 2019-01-24
US20250376540A1 (en) 2025-12-11
CA3070252A1 (en) 2019-01-24
US20200216567A1 (en) 2020-07-09
EP3655432A1 (en) 2020-05-27
CN111094338A (zh) 2020-05-01
US20200216568A1 (en) 2020-07-09
JP2023083385A (ja) 2023-06-15
US11613590B2 (en) 2023-03-28
US20230406960A1 (en) 2023-12-21
WO2019018428A1 (en) 2019-01-24
US20240052063A1 (en) 2024-02-15
JP2020527355A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7690285B2 (ja) 結合タンパク質１
CN116133694B (zh) 抗her3抗体和抗her3抗体药物偶联物及其医药用途
US11033634B2 (en) Light chain variable regions
US20200181256A1 (en) Anti sez6 antibodies and methods of use
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CN114929278A (zh) 抗ccr8抗体及其用途
JP7190901B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
JP6154895B2 (ja) ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
TW201828991A (zh) 用於移除造血幹細胞的抗體藥物結合物
JP7485368B2 (ja) 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
JP2021521817A5 (https=)
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
KR20260046386A (ko) 인간화 muc1 항체 및 항체 약물 접합체
JP2026510185A (ja) Ｆａｓリガンドに対して特異的なモノクローナル抗体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230412

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230424

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230525

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250529

R150 Certificate of patent or registration of utility model

Ref document number: 7690285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150